|
|
|
 |
FDA Approval Activities for this Drug…
Emtriva (emtricitabine) Capsules, 200 mg Gilead Sciences, NDA 21-500 Truvada, (emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg)) tablets, Gilead Sciences, Approval | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision | Emtriva (emtricitabine) Capsules, Gilead Sciences, Labeling Revision | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision | EMTRIVA (emtricitabine) Capsules, Gilead Sciences, Labeling Revision | TRUVADA Tablets, Gilead Sciences, Accelerated Approval | EMTRIVA (emtricitabine) Oral Solution, Gilead Sciences, Patient Population Altered & Labeling Revision | Truvada (emtricitabine/tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision | ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision | Emtriva (emtricitabine) Capsules, Gilead Sciences, Labeling Revision | Emtriva (emtricitabine) Oral Solution, Gilead Sciences, Labeling Revision | Emtricitabine Capsules, Aurobindo Pharma USA, Inc., Tentative Approval | Emtriva (emtricitabine) Capsules, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Emtriva (emtricitabine) Oral Solution, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision | Emtricitabine Capsules, Matrix Laboratories Ltd., Approval | Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, Matrix Laboratories Ltd., Tentative Approval | Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, Laboratories Ltd., Tentative Approval | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision | Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision | Emtricitabine Capsules, Cipla Ltd., Tentative Approval | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision | Complera (emtricitabine, rilpivirine and tenofovir disoproxil fumarate) Fixed Dose Combination Tablets, Gilead Sciences, Inc., Approval | Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision | Efavirenz, Emitricitabine and Tenofovir Disoproxil Fumarate Tablets, TEVA Pharmaceuticals, Tentative Approval | Emtriva (emtricitabine) Capsules, Gilead Sciences, Inc., Labeling Revision | Emtriva (emtricitabine) Oral Solution, Gilead Sciences, Inc., Labeling Revision | Emtricitabine; Tenofovir Disoproxil Fumarate, emtricitabine; tenofovir disoproxil fumarate, Tablet; Oral, Hetero Labs Unit Iii, Tentative Approval
  
|